Mundipharma enters into partnership with Samsung Bioepis to broaden reach of biosimilars to Taiwan and Hong Kong.
Mundipharma, an independent network of companies announced on 13th January 2020 that is has secured a partnership with Samsung Bioepis to commercialize Samsung Bioepis’ first-wave biosimilar candidates in Taiwan and Hong Kong.
Established in 2012, Samsung Bioepis was a joint venture between Samsung BioLogics and Biogen. As a biopharmaceutical company it is committed to providing healthcare that is accessible to everyone. Through innovation in product development and a firm commitment to quality. It continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, and haematology.
Through the partnership, Mundipharma will be the exclusive commercialization partner, while Samsung Bioepis will remain the Marketing Authorisation Holder, responsible for clinical development, regulatory registration, and manufacture of the biosimilars.
The partnership covers Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab), and SB8 (bevacizumab).
“This partnership brings together Samsung Bioepis’ proven biosimilar development platform with Mundipharma’s commercial acumen and market insight and ability to increase patient access to proven treatments,” said Mundipharma CEO, Raman Singh. “This partnership will help to address the patient need in two important territories in Asia for immunology and oncology treatments,” he added. [APBN]